Jiangxi Xinganjiang Pharmaceutical Co (BJSE:920367) Other Stockholders Equity: ¥302.5 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BJSE:920367 Jiangxi Xinganjiang Pharmaceutical Co Ltd BJSE:920367
69 GF Score
Price ¥24.38
GF Value ¥11.91
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Jiangxi Xinganjiang Pharmaceutical Co Other Stockholders Equity?

Jiangxi Xinganjiang Pharmaceutical Co BJSE:920367 69 Other Stockholders Equity is ¥302.5 Mil as of Mar. 2026. GuruFocus rates BJSE:920367 with a GF Score™ of 69/100 and a GF Value™ of ¥11.91 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Jiangxi Xinganjiang Pharmaceutical Co's Other Stockholders Equity for the quarter that ended in Mar. 2026 was ¥302.5 Mil.

Jiangxi Xinganjiang Pharmaceutical Co's quarterly Other Stockholders Equity declined from Sep. 2025 (¥301.9 Mil) to Dec. 2025 (¥26.6 Mil) but then increased from Dec. 2025 (¥26.6 Mil) to Mar. 2026 (¥302.5 Mil).

Jiangxi Xinganjiang Pharmaceutical Co's annual Other Stockholders Equity increased from Dec. 2023 (¥23.8 Mil) to Dec. 2024 (¥25.6 Mil) and increased from Dec. 2024 (¥25.6 Mil) to Dec. 2025 (¥26.6 Mil).

Jiangxi Xinganjiang Pharmaceutical Co Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Jiangxi Xinganjiang Pharmaceutical Co's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jiangxi Xinganjiang Pharmaceutical Co Other Stockholders Equity Chart

Jiangxi Xinganjiang Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -917.74 19.59 23.81 25.55 26.60

Jiangxi Xinganjiang Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 301.84 25.65 301.91 26.60 302.46
BJSE:920367
69GF Score
Jiangxi Xinganjiang Pharmaceutical Co Ltd BJSE:920367
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jiangxi Xinganjiang Pharmaceutical Co Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of ¥302.5 Mil mean?
Jiangxi Xinganjiang Pharmaceutical Co (BJSE:920367) has a Other Stockholders Equity of ¥302.5 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Jiangxi Xinganjiang Pharmaceutical Co and its competitors.
Is Jiangxi Xinganjiang Pharmaceutical Co's Other Stockholders Equity too high?
Jiangxi Xinganjiang Pharmaceutical Co's current Other Stockholders Equity is ¥302.5 Mil. Overall, Jiangxi Xinganjiang Pharmaceutical Co has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jiangxi Xinganjiang Pharmaceutical Co's Other Stockholders Equity compare to ZTS?
Jiangxi Xinganjiang Pharmaceutical Co's Other Stockholders Equity of ¥302.5 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Jiangxi Xinganjiang Pharmaceutical Co and its competitors. Jiangxi Xinganjiang Pharmaceutical Co's current Other Stockholders Equity is ¥302.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangxi Xinganjiang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangxi Xinganjiang Pharmaceutical Co (BJSE:920367) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥11.91, compared to a current price of ¥24.38 — trading 104.7% above its estimated fair value. The current Other Stockholders Equity is ¥302.5 Mil. Jiangxi Xinganjiang Pharmaceutical Co's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Jiangxi Xinganjiang Pharmaceutical Co (BJSE:920367), the current Other Stockholders Equity is ¥302.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jiangxi Xinganjiang Pharmaceutical Co (BJSE:920367) Overvalued in 2026?

Based on GuruFocus' analysis, Jiangxi Xinganjiang Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥24.38 is trading 104.7% above its estimated GF Value™ of ¥11.91. GuruFocus considers Jiangxi Xinganjiang Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for BJSE:920367:

  • Other Stockholders Equity: ¥302.5 Mil
  • GF Value™: ¥11.91 vs. price of ¥24.38 (104.7% above fair value)
  • GF Score™: 69/100 with 4 warning signs

No single metric tells the full story. See the BJSE:920367 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jiangxi Xinganjiang Pharmaceutical Co Business Description

Address No. 36 Yunzhang Road, Industrial Park, Jizhou District, Jiangxi Province, Ji'an City, CHN, 343000
Jiangxi Xinganjiang Pharmaceutical Co Ltd conducts research and development, production, and sales of chemical raw materials, chemical preparations, and Chinese patent medicines. The company's raw material medicine products are mainly calcium gluconate, zinc gluconate, ferrous gluconate, and other gluconate series raw material medicines. Its main chemical preparations are vitamin C chewable tablets and compound Yinqiao aminomin capsules, and Phenaminokamin Tablets.
69GF Score

Get the complete analysis for BJSE:920367

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥24.38
Price
¥11.91
GF Value